Nutriband Inc. is a Nevada-incorporated pharmaceutical development and commercialization company focusing on drug delivery systems engaged in licensing, distribution, and manufacturing partnerships.

# Nutriband Inc. Company Summary

**Company Name:** Nutriband Inc.  
**State of Incorporation:** Nevada  
**Principal Office Address:** 121 South Orange Ave., Suite 1500, Orlando, FL 32801  
**Phone Number:** (407) 377-6695

---

## Business Focus and Activities
Nutriband Inc. is involved in the development and commercialization of pharmaceutical products, with a focus on drug delivery systems. The company appears to engage in licensing, distribution, and potential product development agreements, as evidenced by its extensive list of contracts and agreements related to pharmaceutical licensing, distribution, and manufacturing.

## Corporate Structure & Governance
- The company is classified as a *smaller reporting company* and an *emerging growth company*.
- It has a team of executive officers and directors, including Gareth Sheridan (CEO) and Gerald Goodman (CFO).

## Financial and Shareholder Information
- **Market Capitalization (as of July 31, 2024):** Approximately $44,975,804
- **Shares Outstanding (as of May 13, 2025):** 11,154,171 shares of common stock

## Litigation & Reporting Status
- The company is not a well-known seasoned issuer.
- It has filed the required annual reports and submitted electronic filings.
- There are no indications of being a shell company or having corrected any material errors in prior financial statements.
- The company has not submitted management’s report on internal controls for Section 404(b).

---

## Additional Notes
- The company’s filings include numerous agreements and plans, such as licensed products, employment agreements, distribution, and licensing contracts, highlighting a focus on pharmaceutical licensing, distribution, and manufacturing partnership activities.
- No specific information about revenue, profit, number of customers, or employees has been provided in this document.

Nutriband Inc. is a Nevada corporation focused on developing abuse deterrent transdermal pharmaceutical products utilizing proprietary AVERSA technology to combat opioid and stimulant drug misuse.

# Nutriband Inc. Overview

## Company Description
Nutriband Inc. is a Nevada corporation formed in January 2016, specializing in the development of transdermal pharmaceutical products. The company focuses on utilizing its proprietary AVERSA™ abuse deterrent transdermal technology in its product pipeline, targeting drugs susceptible to abuse and misuse, notably opioid and stimulant drugs.

## Business Operations
- **Primary Business Model**: Nutriband operates primarily through its two subsidiaries:
  - **Pocono Pharmaceuticals (Active Intelligence)**: Provides contract manufacturing services tailored for health, wellness, and over-the-counter pharmaceutical customers.
  - **4P Therapeutics**: Engages in contract research and development for pharmaceutical and medical device clients.

- **Employees**: Nutriband employs a team of specialized personnel dedicated to research and development, clinical trials, and regulatory compliance. Specific employee numbers are not disclosed in the summary.

- **Customers**: Nutriband's revenue generation relies on B2B operations with multiple health and wellness companies primarily focused in the United States.

## Revenue Generation
Nutriband's revenue is derived from:
- Contract manufacturing services via Pocono Pharmaceuticals.
- Contract R&D services through 4P Therapeutics.
  
While exact revenue figures are not provided, the company is in the development phase with its lead product and does not currently have marketed products resulting in significant revenue or operational profit.

## Development Pipeline
- **Main Product**: 
  - **AVERSA Fentanyl**: An abuse deterrent transdermal patch integrating the already approved fentanyl formulation with Nutriband's AVERSA technology.
- **Pipeline Products**:
  - **AVERSA Buprenorphine**: Intended to deter abuse of buprenorphine, an opioid used primarily in opioid addiction treatments.
  - **AVERSA Methylphenidate**: Aiming to deliver methylphenidate (commonly used for ADHD) in an abuse-deterrent formulation.

## Recent Developments
- In April 2024, Nutriband completed an equity financing of $8.4 million with European investors, selling 2.1 million units at $4.00 per unit, which includes shares and warrants.
- The company has entered a partnership with Kindeva Drug Delivery for the commercial development of AVERSA Fentanyl, transitioning from a feasibility agreement to a clinical supply contract.

## Regulatory Environment
Nutriband's products will need to undergo rigorous FDA approval processes, including preclinical and clinical trials. They plan to utilize the 505(b)(2) NDA pathway, which allows for the incorporation of existing safety data from already approved drugs.

## Challenges and Risks
Nutriband faces various risks associated with product development and regulatory approval, including potential delays, the need for additional studies, and market competition. The success of their products heavily relies on the effectiveness of trials and regulatory acceptance.

## Summary
- **Incorporation**: January 2016, Nevada.
- **Primary Focus**: Development of abuse-deterrent transdermal patches with AVERSA technology.
- **Key Products**: AVERSA Fentanyl, AVERSA Buprenorphine, AVERSA Methylphenidate.
- **Revenue Model**: Contract manufacturing and R&D services.
- **Regulatory Path**: Requires FDA approval via a streamlined 505(b)(2) NDA process.

Overall, Nutriband Inc. is positioned in a critical sector addressing the opioid crisis through innovative transdermal delivery solutions, with a potential market impact depending on successful product development and market acceptance.

NutriBand Inc.

10-K / May 13, 2025

10-K / May 1, 2024

10-K / May 13, 2025

Nutriband Inc. Company Summary

Business Focus and Activities

Corporate Structure & Governance

Financial and Shareholder Information

Litigation & Reporting Status

Additional Notes